RGEN - Repligen Corporation

Repligen Corporation develops and manufactures bioprocessing consumables and equipment used in the production of biologic drugs, including its OPUS pre-packed chromatography columns, XCell ATF cell retention systems, and single-use filtration products under the Spectrum brand. The core customer base is biopharmaceutical manufacturers — from large CDMOs to emerging biotech firms — operating under a consumables-driven recurring revenue model where columns and filters are replaced each production run. Repligen generates approximately $700-750M in annual revenue, with the majority derived from North America and Europe, reflecting where most global biologics manufacturing capacity resides. Revenue has been under pressure since 2023 due to customer inventory destocking following the post-COVID biologics manufacturing slowdown.

Past Year Trends

• Repligen reported full-year 2025 revenue of $738 million, a 16% year-over-year increase, marking a broad-based recovery in bioprocessing consumables demand after the 2023-2024 post-COVID inventory destocking cycle. (Bullish)
• Repligen acquired 908 Devices' bioprocessing process analytical technology (PAT) portfolio in March 2025, recognizing $50.1 million in goodwill and adding facilities in North Carolina and Braunschweig, Germany to expand its Analytics franchise. (Bullish)
• The gene therapy segment remained a persistent drag on results, with management explicitly embedding a two-percentage-point gene therapy revenue headwind into full-year 2026 guidance, reflecting continued weak consumable and capital spending by cell and gene therapy customers. (Bearish)

Next Year Trends

• China revenue nearly doubled year-over-year in Q1 2026 following a new APAC distribution partnership and the onboarding of a dedicated General Manager of China; sustained execution in this region could push revenue above the $825 million full-year 2026 guidance midpoint. (Bullish)
• Full-year 2026 revenue guidance of $810M-$840M carries an embedded two-point gene therapy headwind; if cell and gene therapy customer capex and consumable budgets remain depressed beyond current expectations, Repligen risks missing the low end of its own guidance range. (Bearish)
• Repligen guided for 150 basis points of adjusted operating margin expansion in full-year 2026 and raised adjusted EPS guidance to $1.97-$2.05 after Q1 2026 delivered 160 bps of margin expansion, making margin execution the primary lever for EPS upside if revenue lands near the midpoint. (Bullish)

Red Flags

No severe red flags identified as of August 2025.